(Q33819957)

English

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

Lawrence Ginsberg

3

object named as

Lawrence D Ginsberg

1 reference

Europe PubMed Central

29 July 2017

author name string

Thomas J Spencer

1

1 reference

Europe PubMed Central

29 July 2017

Michael Greenbaum

2

1 reference

Europe PubMed Central

29 July 2017

William Rory Murphy

4

1 reference

Europe PubMed Central

29 July 2017

publication date

1 October 2009

1 reference

Europe PubMed Central

29 July 2017

Journal of Child and Adolescent Psychopharmacology

1 reference

Europe PubMed Central

29 July 2017

19

1 reference

Europe PubMed Central

29 July 2017

5

1 reference

Europe PubMed Central

29 July 2017

501-510

1 reference

Europe PubMed Central

29 July 2017

Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Treatment of ADHD in children with tics: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Epidemiology of ADHD in school-age children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Attention deficit disorder: a review of the past 10 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

4 July 2018

Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

29 October 2018

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

29 October 2018

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

29 October 2018

Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

29 October 2018

A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

29 October 2018

Combination pharmacotherapy for adult ADHD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

29 October 2018

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861960

29 October 2018

Delineation of rat kidney α2A- and α2B-adrenoeeptors with [3H]RX821002 radiollgand binding: computer modelling reveals that guanfacine is an α2A-selective compound

1 reference

https://pubmed.ncbi.nlm.nih.gov/19877974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms

1 reference

https://pubmed.ncbi.nlm.nih.gov/19877974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attention-deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/19877974

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1089/CAP.2008.0152

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33819957&oldid=2126767334"